The DOI matches its Crossref record; 103 of the 103 references it cites were found in a registry or an index.
Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia: A Network Meta-analysis
Open accessAbstract
IMPORTANCE: In treatment-resistant schizophrenia, clozapine is considered the standard treatment. However, clozapine use has restrictions owing to its many adverse effects. Moreover, an increasing number of randomized clinical trials (RCTs) of other antipsychotics have been published. OBJECTIVE: To integrate all the randomized evidence from the available antipsychotics used for treatment-resistant schizophrenia by performing a network meta-analysis. DATA SOURCES: MEDLINE, EMBASE, Biosis, PsycINFO, PubMed, Cochrane Central Register of Controlled Trials, World Health Organization International Trial Registry, and clinicaltrials.gov were searched up to June 30, 2014. STUDY SELECTION: At least 2 independent reviewers selected published and unpublished single- and double-blind RCTs in treatment-resistant schizophrenia (any study-defined criterion) that compared any antipsychotic (at any dose and in any form of administration) with another antipsychotic or placebo. DATA EXTRACTION AND SYNTHESIS: At least 2 independent reviewers extracted all data into standard forms and assessed the quality of all included trials with the Cochrane Collaboration's risk-of-bias tool. Data were pooled using a random-effects model in a Bayesian setting. MAIN OUTCOMES AND MEASURES: The primary outcome was efficacy as measured by overall change in symptoms of schizophrenia. Secondary outcomes included change in positive and negative symptoms of schizophrenia, categorical response to treatment, dropouts for any reason and for inefficacy of treatment, and important adverse events. RESULTS: Forty blinded RCTs with 5172 unique participants (71.5% men; mean [SD] age, 38.8 [3.7] years) were included in the analysis. Few significant differences were found in all outcomes. In the primary outcome (reported as standardized mean difference; 95% credible interval), olanzapine was more effective than quetiapine (-0.29; -0.56 to -0.02), haloperidol (-0. 29; -0.44 to -0.13), and sertindole (-0.46; -0.80 to -0.06); clozapine was more effective than haloperidol (-0.22; -0.38 to -0.07) and sertindole (-0.40; -0.74 to -0.04); and risperidone was more effective than sertindole (-0.32; -0.63 to -0.01). A pattern of superiority for olanzapine, clozapine, and risperidone was seen in other efficacy outcomes, but results were not consistent and effect sizes were usually small. In addition, relatively few RCTs were available for antipsychotics other than clozapine, haloperidol, olanzapine, and risperidone. The most surprising finding was that clozapine was not significantly better than most other drugs. CONCLUSIONS AND RELEVANCE: Insufficient evidence exists on which antipsychotic is more efficacious for patients with treatment-resistant schizophrenia, and blinded RCTs-in contrast to unblinded, randomized effectiveness studies-provide little evidence of the superiority of clozapine compared with other second-generation antipsychotics. Future clozapine studies with high doses and patients with extremely treatment-refractory schizophrenia might be most promising to change the current evidence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Power Analysis for the Behavioral Sciences
Muller, K. (1989) · Technometrics · doi:10.1080/00401706.1989.10488618 · Cited by 99,167
Statistical power analysis for the behavioral sciences
(1990) · Computers, Environment and Urban Systems · doi:10.1016/0198-9715(90)90050-4 · Cited by 65,269
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
(1976) · Medical Entomology and Zoology · Cited by 8,899
WinBUGS - A Bayesian modelling framework: Concepts, structure, and extensibility
Lunn, D. J., Thomas, A., Best, N., & Spiegelhalter, D. (2000) · Statistics and Computing · doi:10.1023/a:1008929526011 · Cited by 5,368
Cochrane Handbook for Systematic Reviews of Interventions
Tarsilla, M. (2010) · Journal of MultiDisciplinary Evaluation · doi:10.56645/jmde.v6i14.284 · Cited by 5,178
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
Salanti, G., Ades, A. E., & Ioannidis, J. P. A. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.03.016 · Cited by 3,766
Self-citationHow should meta‐regression analyses be undertaken and interpreted?
Thompson, S. G., & Higgins, J. P. T. (2002) · Statistics in Medicine · doi:10.1002/sim.1187 · Cited by 3,026
Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60733-3 · Cited by 2,561
Self-citationGraphical tools for network meta-analysis in STATA
Chaimani, A., Higgins, J. P. T., Mavridis, D., Spyridonos, P., & Salanti, G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076654 · Cited by 2,473
Self-citationMeta-analyses involving cross-over trials: methodological issues
Elbourne, D. R., Altman, D. G., Higgins, J. P., Curtin, F., Worthington, H. V., & Vail, A. (2002) · International Journal of Epidemiology · doi:10.1093/ije/31.1.140 · Cited by 2,305
Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies
Higgins, J. P. T., Jackson, D., Barrett, J. K., Lu, G., Ades, A. E., & White, I. R. (2012) · Research Synthesis Methods · doi:10.1002/jrsm.1044 · Cited by 2,098
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
Leucht, S., Corves, C., Arbter, D., Engel, R. R., Li, C., & Davis, J. M. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61764-x · Cited by 1,930
Self-citationSalanti, G. (2012) · Research Synthesis Methods · doi:10.1002/jrsm.1037 · Cited by 1,729
Self-citationSimultaneous comparison of multiple treatments: Combining direct and indirect evidence.
Caldwell, D. M., Ades, A. E., & Higgins, J. P. T. (2005) · BMJ · doi:10.1136/bmj.331.7521.897 · Cited by 1,600
Discovering the Neural Basis of Human Social Anxiety: A Diagnostic and Therapeutic Imperative
Charney, D. S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.1.1 · Cited by 1,428
Tiihonen, J., Lönnqvist, J., Wahlbeck, K., Klaukka, T., Niskanen, L., Tanskanen, A., & Haukka, J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60742-x · Cited by 1,354
International Consensus Study of Antipsychotic Dosing
Gardner, D. M., Murphy, A. L., O'Donnell, H., Centorrino, F., & Baldessarini, R. J. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09060802 · Cited by 1,301
Dias, S., Sutton, A. J., Ades, A. E., & Welton, N. J. (2013) · Medical Decision Making · doi:10.1177/0272989x12458724 · Cited by 1,207
White, I. R., Barrett, J. K., Jackson, D., & Higgins, J. P. T. (2012) · Research Synthesis Methods · doi:10.1002/jrsm.1045 · Cited by 1,114
Jones, P. B., Barnes, T. R. E., Davies, L., Dunn, G., Lloyd, H., Hayhurst, K. P., Murray, R. M., Markwick, A., & Lewis, S. W. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.10.1079 · Cited by 1,105
Conceptual and technical challenges in network meta-analysis
Cipriani, A., Higgins, J. P. T., Geddes, J. R., & Salanti, G. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-2-201307160-00008 · Cited by 1,072
Self-citationA Meta-analysis of the Efficacy of Second-Generation Antipsychotics
Davis, J. M., Chen, N., & Glick, I. D. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.6.553 · Cited by 1,034
McEvoy, J. P., Lieberman, J. A., Stroup, T. S., Davis, S. M., Meltzer, H. Y., Rosenheck, R. A., Swartz, M. S., Perkins, D. O., Keefe, R. S. E., Davis, C. E., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.4.600 · Cited by 1,018
Song, F., Altman, D. G., Glenny, A.-M., & Deeks, J. J. (2003) · BMJ · doi:10.1136/bmj.326.7387.472 · Cited by 943
The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements
Buchanan, R. W., Kreyenbuhl, J., Kelly, D. L., Noel, J. M., Boggs, D. L., Fischer, B. A., Himelhoch, S., Fang, B., Peterson, E., Aquino, P. R., et al. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp116 · Cited by 907
The unit of analysis error in studies about physicians' patient care behavior
Divine, G. W., Brown, J. T., & Frazier, L. M. (1992) · Journal of General Internal Medicine · doi:10.1007/bf02599201 · Cited by 749
Dias, S., Welton, N. J., Sutton, A. J., Caldwell, D. M., Lu, G., & Ades, A. E. (2013) · Medical Decision Making · doi:10.1177/0272989x12455847 · Cited by 728
Jansen, J. P., & Naci, H. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-159 · Cited by 656
Hasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Thibaut, F., Möller, H.-J., & the Wfsbp Task Force on Treatment Guidelines for Schizophrenia (2012) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2012.696143 · Cited by 637
Chakos, M., Lieberman, J., Hoffman, E., Bradford, D., & Sheitman, B. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.4.518 · Cited by 631
Barnes, T. R., Drake, R., Paton, C., Cooper, S. J., Deakin, B., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I., et al. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 606
Evaluation of inconsistency in networks of interventions
Veroniki, A. A., Vasiliadis, H. S., Higgins, J. P., & Salanti, G. (2013) · International Journal of Epidemiology · doi:10.1093/ije/dys222 · Cited by 576
Self-citationChaimani, A., & Salanti, G. (2012) · Research Synthesis Methods · doi:10.1002/jrsm.57 · Cited by 521
Self-citationA Comparison of Clozapine and Haloperidol in Hospitalized Patients with Refractory Schizophrenia
Rosenheck, R., Cramer, J., Xu, W., Thomas, J., Henderson, W., Frisman, L., Fye, C., & Charney, D. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709183371202 · Cited by 516
Leucht, S., Komossa, K., Rummel-Kluge, C., Corves, C., Hunger, H., Schmid, F., Asenjo Lobos, C., Schwarz, S., & Davis, J. M. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08030368 · Cited by 490
Self-citationLeucht, S., Arbter, D., Engel, R. R., Kissling, W., & Davis, J. M. (2009) · Molecular Psychiatry · doi:10.1038/sj.mp.4002136 · Cited by 489
Lewis, S. W., Barnes, T. R. E., Davies, L., Murray, R. M., Dunn, G., Hayhurst, K. P., Markwick, A., Lloyd, H., & Jones, P. B. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbj067 · Cited by 422
Volavka, J., Czobor, P., Sheitman, B., Lindenmayer, J.-P., Citrome, L., McEvoy, J. P., Cooper, T. B., Chakos, M., & Lieberman, J. A. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.2.255 · Cited by 407
Dose Equivalents for Second-Generation Antipsychotics: The Minimum Effective Dose Method
Leucht, S., Samara, M., Heres, S., Patel, M. X., Woods, S. W., & Davis, J. M. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu001 · Cited by 372
Self-citationDose Response and Dose Equivalence of Antipsychotics
Davis, J. M., & Chen, N. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000117422.05703.ae · Cited by 358
Wahlbeck, K., Cheine, M., Essali, A., & Adams, C. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.7.990 · Cited by 357
Zhang, J.-P., Gallego, J. A., Robinson, D. G., Malhotra, A. K., Kane, J. M., & Correll, C. U. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712001277 · Cited by 336
Linking the PANSS, BPRS, and CGI: Clinical Implications
Leucht, S., Kane, J. M., Etschel, E., Kissling, W., Hamann, J., & Engel, R. R. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301147 · Cited by 333
Self-citationClozapine versus typical neuroleptic medication for schizophrenia
Essali, A., Al-Haj Haasan, N., Li, C., & Rathbone, J. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000059.pub2 · Cited by 329
Dose Equivalents for Second-Generation Antipsychotic Drugs: The Classical Mean Dose Method
Leucht, S., Samara, M., Heres, S., Patel, M. X., Furukawa, T., Cipriani, A., Geddes, J., & Davis, J. M. (2015) · Schizophrenia Bulletin · doi:10.1093/schbul/sbv037 · Cited by 318
Self-citationA design‐by‐treatment interaction model for network meta‐analysis with random inconsistency effects
Jackson, D., Barrett, J. K., Rice, S., White, I. R., & Higgins, J. P. T. (2014) · Statistics in Medicine · doi:10.1002/sim.6188 · Cited by 304
Bondolfi, G., Dufour, H., Patris, M., May, J. P., Billeter, U., Eap, C. B., & Baumann, P. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.4.499 · Cited by 283
Buchanan, R. W., Breier, A., Kirkpatrick, B., Ball, P., & Carpenter, W. T. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.6.751 · Cited by 264
Quetiapine versus other atypical antipsychotics for schizophrenia
Komossa, K., Rummel-Kluge, C., Schmid, F., Hunger, H., Schwarz, S., Srisurapanont, M., Kissling, W., & Leucht, S. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006625.pub2 · Cited by 260
Self-citationOlanzapine Compared With Chlorpromazine in Treatment-Resistant Schizophrenia
Conley, R. R., Tamminga, C. A., Bartko, J. J., Richardson, C., Peszke, M., Lingle, J., Hegerty, J., Love, R., Gounaris, C., & Zaremba, S. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.7.914 · Cited by 245
Past and Present Progress in the Pharmacologic Treatment of Schizophrenia
Kane, J. M., & Correll, C. U. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10r06264yel · Cited by 232
Randomized trials published in some Chinese journals: how many are randomized?
Wu, T., Li, Y., Bian, Z., Liu, G., & Moher, D. (2009) · Trials · doi:10.1186/1745-6215-10-46 · Cited by 229
Clozapine in treatment-resistant schizophrenics.
Kane, J. M., Honigfeld, G., Singer, J., & Meltzer, H. Y. (1988) · PubMed · Cited by 217
Leucht, S., Davis, J. M., Engel, R. R., Kane, J. M., & Wagenpfeil, S. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301325 · Cited by 216
Self-citationBreier, A. F., Malhotra, A. K., Su, T.-P., Pinals, D. A., Elman, I., Adler, C. M., Lafargue, R. T., Clifton, A., & Pickar, D. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.2.294 · Cited by 208
Tollefson, G. D., Birkett, M. A., Kiesler, G. M., & Wood, A. J. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(00)01026-x · Cited by 202
Clozapine versus other atypical antipsychotics for schizophrenia
Asenjo Lobos, C., Komossa, K., Rummel-Kluge, C., Hunger, H., Schmid, F., Schwarz, S., & Leucht, S. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006633.pub2 · Cited by 188
Self-citationAzorin, J.-M., Spiegel, R., Remington, G., Vanelle, J.-M., Péré, J.-J., Giguere, M., & Bourdeix, I. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.8.1305 · Cited by 179
Kane, J. M., Marder, S. R., Schooler, N. R., Wirshing, W. C., Umbricht, D., Baker, R. W., Wirshing, D. A., Safferman, A., Ganguli, R., McMeniman, M., et al. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.10.965 · Cited by 178
Meltzer, H. Y., Bobo, W. V., Roy, A., Jayathilake, K., Aygun, C., Elif, E. A., Yagcioglu, A., & Small, J. G. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0214 · Cited by 176
Emsley, R. A., Raniwalla, J., Bailey, P. J., & Jones, A. M. (2000) · International Clinical Psychopharmacology · doi:10.1097/00004850-200015030-00001 · Cited by 175
Placebo Response in Antipsychotic Clinical Trials
Rutherford, B. R., Pott, E., Tandler, J. M., Wall, M. M., Roose, S. P., & Lieberman, J. A. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.1319 · Cited by 152
Risperidone in Treatment-Refractory Schizophrenia
Wirshing, D. A., Marshall, B. D., Green, M. F., Mintz, J., Marder, S. R., & Wirshing, W. C. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.9.1374 · Cited by 148
Meta-analyses involving cross-over trials: methodological issues
Stedman, M. R., Curtin, F., Elbourne, D. R., Kesselheim, A. S., & Brookhart, M. A. (2009) · International Journal of Epidemiology · doi:10.1093/ije/dyp345 · Cited by 148
Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia
Bitter, I., Dossenbach, M. R. K., Brook, S., Feldman, P. D., Metcalfe, S., Gagiano, C. A., Füredi, J., Bartkó, G., Janka, Z., Bánki, C. M., et al. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2003.09.033 · Cited by 147
Extrapolation between measures of symptom severity and change: An examination of the PANSS and CGI
Levine, S. Z., Rabinowitz, J., Engel, R. R., Etschel, E., & Leucht, S. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.09.006 · Cited by 144
Self-citationClozapine versus typical neuroleptic medication for schizophrenia
Wahlbeck, K., Cheine, M. V., & Essali, A. (1999) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000059 · Cited by 144
Meta-Regression Analysis of Placebo Response in Antipsychotic Trials, 1970–2010
Agid, O., SIU, C. O., Potkin, S. G., Kapur, S., Watsky, E. J., Vanderburg, D. G., Zipursky, R. B., & Remington, G. J. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.12030315 · Cited by 140
Network meta-analysis: a norm for comparative effectiveness?
Higgins, J. P. T., & Welton, N. J. (2015) · The Lancet · doi:10.1016/s0140-6736(15)61478-7 · Cited by 133
Treatment of neuroleptic-resistant schizophrenic relapse.
Kinon, B. J., Kane, J. M., Johns, C. A., et al. (1993) · PubMed · Cited by 132
Kane, J. M., Meltzer, H. Y., Carson, W. H., et al. (2007) · PubMed · Cited by 128
Breier, A. F., & Hamilton, S. H. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00291-1 · Cited by 126
Naber, D., Riedel, M. J., Klimke, A., Vorbach, E.-U., Lambert, M., Kühn, K. ‐., Bender, S., Bandelow, B., Lemmer, W., Moritz, S., et al. (2005) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2004.00486.x · Cited by 102
Clozapine versus other atypical antipsychotics for schizophrenia
Lobos, C. A., Komossa, K., Rummel‐Kluge, C., Hunger, H., Schmid, F., Schwarz, S., & Leucht, S. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006633 · Cited by 95
Self-citationConley, R. R., Kelly, D. L., Richardson, C. M., Tamminga, C. A., & Carpenter, W. T. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000096246.29231.73 · Cited by 90
The Effects of Clozapine and Risperidone on Spatial Working Memory in Schizophrenia
McGurk, S. R., Carter, C., GOLDMAN, R. S., Green, M. F., Marder, S. R., Xie, H., Schooler, N. R., & Kane, J. M. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.5.1013 · Cited by 89
Essock, S. M., Frisman, L. K., Covell, N. H., & Hargreaves, W. A. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.10.987 · Cited by 85
The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements
Buchanan, R. W., Kreyenbuhl, J. A., Kelly, D. L., Noel, J. M., Boggs, D. L., Fischer, B. A., Himelhoch, S. S., Fang, B., Peterson, E., Aquino, P. R., et al. (2012) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.10.2.194 · Cited by 85
Double-Blind Study of Clozapine Dose Response in Chronic Schizophrenia
Simpson, G. M., Josiassen, R. C., Stanilla, J. K., de León, J., Nair, C., Abraham, G., Odom-White, A., & Turner, R. M. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1744 · Cited by 84
Weitoft, G. R., Berglund, M., Lindström, E., Nilsson, M., Salmi, P., & Rosén, M. (2014) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3567 · Cited by 80
Risperidone versus clozapine in treatment-resistant schizophrenia: A randomized pilot study
Wahlbeck, K., Cheine, M. V., Tuisku, K., Ahokas, A., Joffe, G., & Rimón, R. (2000) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(00)00118-4 · Cited by 76
Sacchetti, E., Galluzzo, A., Valsecchi, P., Romeo, F., Gorini, B., & Warrington, L. E. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.02.017 · Cited by 66
Efficacy and tolerability of ziprasidone in patients with treatment-resistant schizophrenia
Kane, J. M., Khanna, S., Rajadhyaksha, S., & Giller, E. L. (2005) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000182114.65134.81 · Cited by 65
Conley, R. R., Kelly, D. L., Nelson, M. W., Richardson, C. M., Feldman, S. M., Benham, R., Steiner, P., Yu, Y., Khan, I., McMullen, R., et al. (2005) · Clinical Neuropharmacology · doi:10.1097/01.wnf.0000172993.89879.0f · Cited by 64
Hong, C.-J., Chen, J., Chiu, H.-J., & Sim, C. (1997) · International Clinical Psychopharmacology · doi:10.1097/00004850-199705000-00001 · Cited by 61
Olanzapine Treatment of Residual Positive and Negative Symptoms
Buchanan, R. W., Ball, M. P., Weiner, E., Kirkpatrick, B. W., Gold, J. M., McMahon, R. P., & Carpenter, W. T. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.1.124 · Cited by 59
Dose Response and Atypical Antipsychotics in Schizophrenia
Kinon, B. J., AHL, J. S. B., Stauffer, V. L., Hill, A. L., & Buckley, P. F. (2004) · CNS Drugs · doi:10.2165/00023210-200418090-00005 · Cited by 58
Maintaining Reviews: Updates, Amendments and Feedback
Higgins, J. P., Green, S., & Scholten, R. J. (2008) · Cochrane Handbook for Systematic Reviews of Interventions · doi:10.1002/9780470712184.ch3 · Cited by 54
Clozapine use in childhood and adolescent schizophrenia: A nationwide population-based study
Schneider, C., Papachristou, E., Wimberley, T., Gasse, C., Dima, D., MacCabe, J. H., Mortensen, P. B., & Frangou, S. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.02.003 · Cited by 54
Bian, Z. (2006) · Journal of Chinese Integrative Medicine · doi:10.3736/jcim20060204 · Cited by 50
Moresco, R. M., Cavallaro, R., Messa, C., Bravi, D., Gobbo, C. L., Galli, L., Lucignani, G., Colombo, C., Rizzo, G., Velonà, I., et al. (2004) · Journal of Psychopharmacology · doi:10.1177/026988110401800306 · Cited by 43
Kane, J. M., Potkin, S. G., Daniel, D. G., & Buckley, P. F. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.07m03733yel · Cited by 42
Brunoni, A. R., Tadini, L., & Fregni, F. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009479 · Cited by 40
Ciudad, A., Haro, J. M., Alonso, J., Bousoño, M., Suarez, D. L., Novick, D., & Gilaberte, I. (2007) · European Psychiatry · doi:10.1016/j.eurpsy.2007.09.008 · Cited by 29
See, R. E., Fido, A. A., Maurice, M., Ibrahim, M. M., & Salama, G. M. S. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00199-1 · Cited by 27
Evaluation of inconsistency in networks of interventions
Veroniki, A. A., Vasiliadis, H. S., Higgins, J. P. T., & Salanti, G. (2013) · International Journal of Epidemiology · doi:10.1093/ije/dyt106 · Cited by 22
Self-citationAltamura, A. C., Velonà, I., Curreli, R., Mundo, E., & Bravi, D. (2002) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/136515002753724117 · Cited by 17
Nyakyoma, K., & Morriss, R. K. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4290 · Cited by 8
Cited by
Cipriani, A., Zhou, X., Del Giovane, C., Hetrick, S. E., Qin, B., Whittington, C., Coghill, D., Zhang, Y., Hazell, P., Leucht, S., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30385-3 · Cited by 734
Self-citationTreatment resistance in psychiatry: state of the art and new directions
Howes, O. D., Thase, M. E., & Pillinger, T. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01200-3 · Cited by 413
Guidelines for the Pharmacotherapy of Schizophrenia in Adults
Remington, G., Addington, D., Honer, W., Ismail, Z., Raedler, T., & Teehan, M. (2017) · The Canadian Journal of Psychiatry · doi:10.1177/0706743717720448 · Cited by 332
Masuda, T., Misawa, F., Takase, M., Kane, J. M., & Correll, C. U. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2019.1702 · Cited by 319
Treatment resistant schizophrenia: Clinical, biological, and therapeutic perspectives
Nucifora, F. C., Woznica, E., Lee, B. J., Cascella, N., & Sawa, A. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.08.016 · Cited by 304
Metadata
- Authors
- Samara, M. T., Dold, M., Gianatsi, M., Nikolakopoulou, A., Helfer, B., Salanti, G., & Leucht, S.
- Venue
- JAMA Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 2016-03-01
- Volume
- 73
- Issue
- 3
- Pages
- 199
- ISSN
- 2168-622X (ISSN-L)
- OpenAlex
- W2270975510
- Cited by
- 300
- References
- 103
- FWCI
- 31.30
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.